Recruitment Status

Not yet recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3240

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Coronary Artery Disease
Interventions: RespirAct; Device
Lead sponsor: Indiana University; Other
Eligibility: 45 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Nadofaragene Firadenovec, Durvalumab, Gemcitabine, Cisplatin, Radical Cystectomy, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Treatment-refractory Obsessive-compulsive Disorder (trOCD)
Interventions: Radiosurgical anterior capsulotomy; Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Dry Eye
Interventions: TRYPTYR Eye Drops, Purilens Plus Non-Preserved Saline Eye Drops; Drug · Other
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Obese Adults
Interventions: Placebo, Tirzepatide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Atrial Fibrillation (AF), Pulmonary Embolism (PE), Left Atrial Appendage Thrombosis
Interventions: Delayed Un-gated CT Scan for Left Atrial Appendage Thrombus, Delayed Gated CT Scan for Left Atrial Appendage Thrombus; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Thrombocytopenia
Interventions: Avatrombopag; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Major Depression
Interventions: Psilocybin, modafinil, zolpidem, pimavanserin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Minneapolis, Minnesota + 1 more

Conditions: Sepsis
Interventions: Epic Sepsis Model Version - 1, Epic Sepsis Model Version - 2, Emory Sepsis Model; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 7
States / cities: Atlanta, Georgia • Decatur, Georgia • Johns Creek, Georgia + 1 more

Conditions: Erythrocytosis, Pulmonary Hypertension, Thrombosis
Interventions: Belzutifan; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Transplant Associated Microangiopathy TAM, Transplant Complication
Interventions: Not listed
Lead sponsor: Manuel Ricardo Espinoza-Gutarra; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: NMIBC, MIBC, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer
Interventions: This is a non-interventional, observational, prospective study.; Other
Lead sponsor: Bladder Cancer Advocacy Network; Other
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Dallas, Texas

Not yet recruiting clinical trials

Filter and sort this status page

Live official records

Needle Free Assessment of Myocardial Oxygenation in Healthy Subjects

Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

Linear Accelerator Radiosurgical Anterior Capsulotomy With Task-based fMRI Identification of PERSonalized and PrEdictiVE Biomarkers of REsponse in Treatment-Refractory Obsessive-Compulsive Disorder (PERSEVERE Trial)

Cooling Eyedrops for Dry Eye

Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity

Exclusion of Left Atrial Appendage Thrombus in Emergency Department Patients With Atrial Fibrillation Undergoing CT to Assess for Pulmonary Embolus: A Feasibility Study

Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias

Psilocybin for Depression in Veterans

Comparison of Sepsis Prediction Algorithms

Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis

Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)

Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)